Glomerulonephritis is a group of kidney conditions in which the tiny filtering units of the kidney become inflamed, often because the immune system is mistakenly attacking kidney tissue. For certain severe, antibody-driven forms of this disease, nephrology teams may consider plasmapheresis for glomerulonephritis as part of a broader treatment plan. Also called therapeutic plasma exchange (TPE), this procedure is designed to physically remove circulating antibodies and immune complexes from the blood that are thought to be driving kidney inflammation.
This article explains what glomerulonephritis is, why plasmapheresis for kidney disease is used in specific antibody-mediated subtypes, what the clinical evidence and guideline recommendations actually show, and what safety considerations patients should understand. This is educational information only – plasmapheresis for severe glomerulonephritis is a specialist-directed therapy that requires evaluation and ongoing supervision by a nephrologist.
What Is Glomerulonephritis?
Glomerulonephritis (GN) refers to inflammation of the glomeruli, the microscopic structures inside the kidneys responsible for filtering waste and excess fluid from the blood. When the glomeruli are damaged, the kidneys may lose their ability to filter properly, which can lead to blood or protein in the urine, high blood pressure, fluid retention, and, in severe cases, declining kidney function.
Several distinct diseases fall under the glomerulonephritis umbrella, and they are not all treated the same way. According to the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases, subtypes relevant to antibody-mediated injury and apheresis-based treatment include:
- Anti-GBM disease (Goodpasture syndrome): A rare condition in which antibodies directly target the glomerular basement membrane, and may also attack the lungs, sometimes causing pulmonary hemorrhage alongside rapidly progressive kidney injury.
- ANCA-associated vasculitis (AAV) with rapidly progressive glomerulonephritis: An autoimmune vasculitis in which anti-neutrophil cytoplasmic antibodies are associated with small-vessel inflammation, including in the kidney.
- Lupus nephritis: Kidney inflammation associated with systemic lupus erythematosus, in which immune complexes deposit in the glomeruli.
These antibody- and immune-complex-mediated subtypes are the primary context in which plasmapheresis for glomerulonephritis has been studied, because the underlying pathogenic molecules circulate in the plasma and, in theory, can be reduced through plasma removal and replacement (KDIGO, Kidney International, 2021).
How Plasmapheresis Works for Antibody-Mediated Kidney Disease
Plasmapheresis, or therapeutic plasma exchange, is a procedure in which blood is drawn from the body, the plasma component is separated from blood cells using a cell separator, and the plasma – along with the antibodies, immune complexes, and inflammatory proteins it carries – is removed and replaced with a substitution fluid such as albumin or, in some bleeding-risk situations, fresh frozen plasma. The blood cells are then returned to the patient. Our complete guide to plasmapheresis covers the procedure itself for readers who want a broader introduction.
In the context of therapeutic plasma exchange for glomerulonephritis, the rationale is mechanistic: conditions like anti-GBM disease are driven by a measurable, circulating autoantibody, so directly removing that antibody from the plasma is thought to reduce the ongoing immune assault on the kidney more rapidly than immunosuppressive medication alone, which works by suppressing new antibody production rather than clearing what is already circulating (Kaplan, Journal of Clinical Apheresis, 2013). This is why plasma exchange is typically used as an adjunct to, not a replacement for, immunosuppressive therapy such as glucocorticoids and cyclophosphamide or rituximab – the medications address the underlying immune process while plasma exchange addresses the immediate antibody burden.
Because the benefit of this approach appears tied to diseases with a clear circulating pathogenic antibody, plasmapheresis is not considered an appropriate or evidence-supported option for most other, non-antibody-mediated forms of kidney disease.
The Clinical Evidence for Plasmapheresis in Glomerulonephritis
The evidence base for plasmapheresis for glomerulonephritis varies considerably by subtype, and clinical guidelines reflect this nuance rather than treating plasma exchange as a uniform intervention.
Anti-GBM disease. The strongest rationale for plasma exchange in glomerulonephritis comes from anti-GBM disease. A landmark long-term outcome study of 71 patients treated with plasma exchange, glucocorticoids, and cyclophosphamide found that patients who were not yet dialysis-dependent at diagnosis had substantially better renal survival than those who already required dialysis, suggesting that earlier initiation of plasma exchange may be associated with better kidney outcomes (Levy et al., Annals of Internal Medicine, 2001). The KDIGO 2021 guideline reflects this evidence by recommending plasma exchange be continued until anti-GBM antibody titers become undetectable, alongside immunosuppression, in patients with sustained potential for kidney recovery (KDIGO, Kidney International, 2021).
ANCA-associated vasculitis (rapidly progressive GN). The evidence here is more mixed. The PEXIVAS trial, the largest randomized trial in this field, randomized 704 patients with severe ANCA-associated vasculitis and kidney or lung involvement to receive plasma exchange or not, in addition to standard immunosuppression. The trial found that adding plasma exchange did not significantly reduce the composite risk of death or end-stage kidney disease (hazard ratio 0.86; 95% CI, 0.65–1.13) (Walsh et al. (PEXIVAS), New England Journal of Medicine, 2020). A subsequent systematic review and meta-analysis similarly reported that plasma exchange had no clear effect on mortality in AAV, some signal toward reduced short-term risk of end-stage kidney disease, but an increased risk of serious infections (Yamada et al., Arthritis Research & Therapy, 2021). As a result, current guideline recommendations reserve plasma exchange in AAV for select patients, such as those with very severe kidney impairment or overlapping anti-GBM antibodies, rather than routine use in all rapidly progressive GN (KDIGO, Kidney International, 2021).
Lupus nephritis. Evidence for plasma exchange in lupus nephritis is the least supportive of the three. An early multicenter controlled trial in severe lupus nephritis found that adding plasmapheresis to standard prednisone and cyclophosphamide therapy did not improve renal outcomes compared with standard therapy alone (Lewis et al., New England Journal of Medicine, 1992). For this reason, plasma exchange is not considered standard therapy for typical lupus nephritis, though it may still be used in specific complications such as concurrent thrombotic microangiopathy or catastrophic antiphospholipid syndrome, under specialist direction.
Taken together, this body of research indicates that plasmapheresis for kidney disease is not a one-size-fits-all intervention – its evidence and guideline support are strongest for anti-GBM disease, more selective for ANCA-associated vasculitis, and limited for lupus nephritis. For a look at how the same procedure is used in other autoimmune conditions, see how plasmapheresis helps autoimmune conditions.
Safety Considerations and What Patients Should Know
Therapeutic plasma exchange for glomerulonephritis is generally performed in a hospital or specialized apheresis unit under nephrology supervision, and it carries risks that patients should discuss with their care team before starting treatment.
- Vascular access complications. Plasma exchange typically requires a large-bore catheter or fistula, which carries a risk of bleeding, infection, or clotting at the access site.
- Infection risk. Because plasma exchange removes antibodies indiscriminately, including protective immunoglobulins, it may temporarily increase susceptibility to infection – a risk that clinical trial data suggest is compounded when combined with intensive immunosuppression (Walsh et al. (PEXIVAS), New England Journal of Medicine, 2020; Yamada et al., Arthritis Research & Therapy, 2021).
- Hemodynamic and electrolyte shifts. Fluid shifts during the procedure may cause low blood pressure, and citrate anticoagulation used during the process can lower calcium levels, sometimes causing tingling or muscle cramps.
- Replacement fluid reactions. Allergic reactions to albumin or fresh frozen plasma replacement fluid are possible, though uncommon.
- Need for concurrent immunosuppression. Plasma exchange is not typically used alone; it is generally paired with glucocorticoids and other immunosuppressive medications, each of which carries its own monitoring requirements.
Because glomerulonephritis subtypes differ so significantly in prognosis and appropriate treatment, a confirmed diagnosis – usually via kidney biopsy and antibody testing – is an essential first step before plasma exchange is considered. Decisions about whether and how to use plasmapheresis should always be individualized and made in partnership with a nephrologist.
Frequently Asked Questions
Is plasmapheresis a cure for glomerulonephritis?
No. Plasmapheresis is not a cure. It is an adjunct treatment that may help reduce circulating antibodies in specific antibody-mediated subtypes of glomerulonephritis, and it is used alongside, not instead of, immunosuppressive medication and nephrology care.
Which types of glomerulonephritis is plasmapheresis used for?
Plasmapheresis for glomerulonephritis is most strongly supported for anti-GBM disease (Goodpasture syndrome). It may also be considered selectively in severe ANCA-associated vasculitis or in specific complications of lupus nephritis, based on individual clinical circumstances.
How many plasmapheresis sessions are typically needed?
The number and frequency of sessions vary by condition and clinical response. In anti-GBM disease, treatment protocols in the literature have generally involved daily or near-daily sessions until antibody levels become undetectable, as directed by the treating nephrology team.
Does plasmapheresis work for all forms of kidney disease?
No. The supporting evidence applies specifically to conditions driven by circulating antibodies or immune complexes. It is not an established or evidence-supported treatment for most other causes of chronic kidney disease.
What are the main risks of plasma exchange?
Reported risks include vascular access complications, increased infection susceptibility, low blood pressure or electrolyte shifts during treatment, and reactions to replacement fluids. These risks are weighed against potential benefit on a case-by-case basis by the care team.
Is plasmapheresis the same as dialysis?
No. Dialysis filters waste products and excess fluid from the blood to replace lost kidney function. Plasmapheresis instead separates and removes plasma components, such as antibodies, and is used for a different therapeutic purpose, though both use similar extracorporeal blood-filtering equipment.
Did the PEXIVAS trial show plasma exchange helps ANCA-associated vasculitis?
The PEXIVAS trial found that adding plasma exchange to standard immunosuppression did not significantly lower the combined risk of death or end-stage kidney disease in severe ANCA-associated vasculitis, which is why its use in this subtype is now more selective rather than routine.
Can plasmapheresis be used for lupus nephritis?
Randomized trial data have not shown that adding plasmapheresis to standard therapy improves outcomes in typical severe lupus nephritis, so it is not considered standard care for this condition, though specialists may consider it in select complicated cases.
Who performs plasmapheresis for kidney disease?
Plasma exchange is performed by trained apheresis teams, typically in a hospital or specialized outpatient apheresis center, under the direction and ongoing supervision of a nephrologist or other specialist physician.
Key Takeaways
- Plasmapheresis for glomerulonephritis is an adjunct therapy aimed at removing circulating antibodies or immune complexes in specific antibody-mediated kidney disease subtypes.
- The strongest evidence and guideline support for plasma exchange is in anti-GBM disease (Goodpasture syndrome), particularly when started before a patient becomes dialysis-dependent.
- In ANCA-associated vasculitis, the PEXIVAS trial found no significant reduction in death or end-stage kidney disease with added plasma exchange, so its use is now more selective.
- Randomized data have not shown benefit from adding plasmapheresis to standard therapy in typical severe lupus nephritis.
- Therapeutic plasma exchange for glomerulonephritis carries real risks, including infection and vascular access complications, and requires nephrology supervision.
- A confirmed diagnosis through biopsy and antibody testing is essential before plasma exchange is considered.
Understanding your kidney health starts with knowing what is actually happening at the cellular level, which is why comprehensive diagnostics matter alongside specialist care. If you want to better understand your options around plasmapheresis or plasma exchange as part of a broader personalized wellness plan, you can schedule a consultation with the Ways2Well team to discuss your individual health picture.
References
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. “Executive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.” Kidney International, 2021;100(4):753-779. DOI: https://doi.org/10.1016/j.kint.2021.05.015
- Kaplan AA. “Therapeutic Plasma Exchange: A Technical and Operational Review.” Journal of Clinical Apheresis, 2013;28(1):3-10. DOI: https://doi.org/10.1002/jca.21257
- Levy JB, Turner AN, Rees AJ, Pusey CD. “Long-Term Outcome of Anti-Glomerular Basement Membrane Antibody Disease Treated with Plasma Exchange and Immunosuppression.” Annals of Internal Medicine, 2001;134(11):1033-1042. DOI: https://doi.org/10.7326/0003-4819-134-11-200106050-00009
- Walsh M, Merkel PA, Peh CA, et al. (PEXIVAS Investigators). “Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.” New England Journal of Medicine, 2020;382(7):622-631. DOI: https://doi.org/10.1056/NEJMoa1803537
- Yamada Y, Harada M, Hara Y, Iwabuchi R, Hashimoto K, Yamamoto S, Kamijo Y. “Efficacy of Plasma Exchange for Antineutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis: A Systematic Review and Meta-Analysis.” Arthritis Research & Therapy, 2021;23:28. DOI: https://doi.org/10.1186/s13075-021-02415-z
- Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM (The Lupus Nephritis Collaborative Study Group). “A Controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis.” New England Journal of Medicine, 1992;326(21):1373-1379. DOI: https://doi.org/10.1056/NEJM199205213262101
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member